Novel Treatment Strategies for Liver Disease Due to a1-Antitrypsin Deficiency

Clinical and Translational Science

Volumn 5, Issue 3, 2012, Pages 289-294

  Maurice, Nicholas ^a   Perlmutter, David H ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Alpha 1 antitrypsin; AT deficiency; Liver disease

Indexed keywords

ALPHA 1 ANTITRYPSIN; CARBAMAZEPINE; CYCLOSPORIN A; POLYMER; SERINE PROTEINASE INHIBITOR;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ALPHA HELIX; APOPTOSIS; ARTICLE; BETA SHEET; CYTOTOXICITY; DISEASE SEVERITY; DRUG EFFICACY; ENDOPLASMIC RETICULUM; ENZYME DEGRADATION; HISTOLOGY; HUMAN; HYDROPHOBICITY; IMMUNOSUPPRESSIVE TREATMENT; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FIBROSIS; LOSS OF FUNCTION MUTATION; NONHUMAN; POINT MUTATION; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN FIBROBLAST; UNFOLDED PROTEIN RESPONSE;

ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MUTATION; PROTEOLYSIS; SIGNAL TRANSDUCTION;

EID: 84862232303     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/j.1752-8062.2011.00363.x     Document Type: Article

References (41)

1. Perlmutter DH. Alpha-1-antitrypsin deficiency: importance of proteasomal and autophagic degradative pathways in disposal of liver disease-associated protein aggregates. Annu Rev Med. 2011; 62: 333-345.
2. Perlmutter DH. Pathogenesis of chronic liver injury and hepatocellular carcinoma in alpha-1-antitrypsin deficiency. Pediatr Res. 2006; 60: 233-238.
3. Perlmutter DH. Liver injury in alpha1-antitrypsin deficiency: an aggregated protein induces mitochondrial injury. J Clin Invest. 2002; 110: 1579-1583.
4. Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200, 000 infants. N Engl J Med. 1976; 294: 1316-1321.
5. Piitulainen E, Carlson J, Ohlsson K, Sveger T. Alpha1-antitrypsin deficiency in 26-year-old subjects: lung, liver, and protease/protease inhibitor studies. Chest. 2005; 128: 2076-2081.
6. Crystal RG. Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. J Clin Invest. 1990; 85: 1343-1352.
7. Janus ED, Phillips NT, Carrell RW. Smoking, lung function, and a1-antitrypsin deficiency. Lancet. 1985; 1: 152-154.
8. Silverman GA, Whisstock JC, Bottomley SP, Huntington JA, Kaiserman D, Luke CJ, Pak SC, Reichhart JM, Bird PI. Serpins flex their muscle: I. Putting the clamps on proteolysis in diverse biological systems. J Biol Chem. 2010; 285: 24, 299-24, 305.
9. Hidvegi T, Ewing M, Hale P, Dippold C, Beckett C, Kemp C, Maurice N, Mukherjee A, Goldbach C, Watkins S, et al. An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science. 2010; 329: 229-232.
10. Gosai SJ, Kwak JH, Luke CJ, Long OS, King DE, Kovatch KJ, Johnston PA, Shun TY, Lazo JS, Perlmutter DH, et al. Automated high-content live animal drug screening using C. elegans expressing the aggregation prone serpin a1-antitrypsin Z. PLoS One. 2010; 12: e15460.
11. Rudnick DA, Liao Y, An JK, Muglia LJ, Perlmutter DH, Teckman JH. Analyses of hepatocellular proliferation in a mouse model of alpha-1-antitrypsin deficiency. Hepatology. 2004; 39: 1048-1055.
12. Rudnick DA, Perlmutter DH. Alpha-1 antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in genetic liver diseases. Hepatology. 2005; 42: 514-521.
13. Ding J, Yannam GR, Roy-Chowdhury N, Hidvegi T, Basma H, Rennard SI, Wong RJ, Avsar Y, Guha C, Perlmutter DH, et al. Spontaneous hepatic repopulation in transgenic mice expressing mutant human a1-antitrypsin by wild-type donor hepatocytes. J Clin Invest. 2011; 121: 1930-1934.
14. Cruz PE, Mueller C, Cossette TL, Golant A, Tang Q, Beattie SG, Brantly M, Campbell-Thompson M, Blomenkamp KS, Teckman JH, et al. In vivo post-transcriptional gene silencing of alpha-1 antitrypsin by adeno-associated virus vectors expressing siRNA. Lab Invest. 2007; 87: 893-902.
15. Huntington JA. Shape-shifting serpins - advantages of a mobile mechanism. Trends Biochem Sci. 2006; 31: 429-435.
16. Yamasaki M, Li W, Johnson DJ, Huntington JA. Crystal structure of a stable dimer reveals the molecular basis of serpin polymerization. Nature. 2008; 455: 1255-1258.
17. Carlson JA, Rogers BB, Sifers RN, Hawkins HK, Finegold MJ, Woo SL. Multiple tissues express alpha 1-antitrypsin in transgenic mice and man. J Clin Invest. 1988; 82: 26-36.
18. Carlson JA, Rogers BB, Sifers RN, Finegold MJ, Clift SM, DeMayo FJ, Bullock DW, Woo SL. Accumulation of PiZ alpha 1-antitrypsin causes liver damage in transgenic mice. J Clin Invest. 1989; 83: 1183-1190.
19. Teckman JH, An JK, Blomenkamp K, Schmidt B, Perlmutter D. Mitochondrial autophagy and injury in the liver in alpha 1-antitrypsin deficiency. Am J Physiol Gastrointest Liver Physiol. 2004; 286: G851-G862.
20. Teckman JH, Perlmutter DH. Retention of mutant alpha(1)-antitrypsin Z in endoplasmic reticulum is associated with an autophagic response. Am J Physiol Gastrointest Liver Physiol. 2000; 279: G961-G974.
21. Teckman JH, An JK, Loethen S, Perlmutter DH. Fasting in alpha1-antitrypsin deficient liver: constitutive activation of autophagy. Am J Physiol Gastrointest Liver Physiol. 2003; 283: G1156-G1165.
22. Hidvegi T, Schmidt BZ, Hale P, Perlmutter DH. Accumulation of mutant alpha1-antitrypsin Z in the endoplasmic reticulum activates caspases-4 and -12, NFkappaB, and BAP31 but not the unfolded protein response. J Biol Chem. 2005; 280: 39, 002-39, 015.
23. Marcus NY, Brunt EM, Blomenkamp K, Ali F, Rudnick DA, Ahmad M, Teckman JH. Characteristics of hepatocellular carcinoma in a murine model of alpha-1-antitrypsin deficiency. Hepatol Res. 2010; 40: 641-653.
24. Eriksson S, Carlson J, Velez R. Risk of cirrhosis and primary liver cancer in alpha 1 antitrypsin deficiency. N Engl J Med. 1986; 314: 736-739.
25. Wu Y, Whitman I, Molmenti E, Moore K, Hippenmeyer P, Perlmutter DH. A lag in intracellular degradation of mutant alpha 1-antitrypsin correlates with the liver disease phenotype in homozygous PiZZ alpha 1-antitrypsin deficiency. Proc Natl Acad Sci USA. 1994; 91: 9014-9018.
26. Qu D, Teckman JH, Omura S, Perlmutter DH. Degradation of a mutant secretory protein, alpha1-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity. J Biol Chem. 1996; 271: 22, 791-22, 795.
27. Werner ED, Brodsky JL, McCracken AA. Proteasome-dependent endoplasmic reticulum-associated protein degradation: an unconventional route to a familiar fate. Proc Natl Acad Sci USA. 1996; 93: 13, 797-13, 801.
28. Teckman JH, Burrows J, Hidvegi T, Schmidt B, Hale PD, Perlmutter DH. The proteasome participates in degradation of mutant alpha 1-antitrypsin Z in the endoplasmic reticulum of hepatoma derived hepatocytes. J Biol Chem. 2001; 276: 44, 865-44, 872.
29. Teckman JH, Gilmore R, Perlmutter DH. Role of ubiquitin in proteasomal degradation of mutant a1-antitrypsin Z in the endoplasmic reticulum. Am J Physiol Gastrointest Liver Physiol. 2000; 278:G39-G48.
30. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science. 2000; 290: 1717-1721.
31. Kamimoto T, Shoji S, Hidvegi T, Mizushima N, Umebayashi K, Perlmutter DH, Yoshimori T. Intracellular inclusions containing mutant alpha1-antitrypsin Z are propagated in the absence of autophagic activity. J Biol Chem. 2006; 281: 4467-4476.
32. Kruse KB, Brodsky JL, McCracken AA. Characterization of an ERAD gene as VPS30/ATG6 reveals two alternative and functionally distinct protein quality control pathways: one for soluble Z variant of human alpha-1 proteinase inhibitor (A1PiZ) and another for aggregates of A1PiZ. Mol Biol Cell. 2006; 17: 203-212.
33. Pan S, Huang L, McPherson J, Muzny D, Rouhani F, Brantly M, Gibbs R, Sifers RN. Single-nucleotide polymorhphism-mediated translational suppression of endoplasmic reticulum mannodisase I modifies the onset of end-stage liver disease in alpha-1 antitrypsin deficiency. Hepatology. 2009; 50: 275-281.
34. Hidvegi T, Mirnics K, Hale P, Ewing M, Beckett C, Perlmutter DH. Regulator of G Signaling 16 is a marker for the distinct endoplasmic reticulum stress state associated with aggregated mutant alpha1-antitrypsin Z in the classical form of alpha1-antitrypsin deficiency. J Biol Chem. 2007; 282: 27, 769-27, 780.
35. Chen C, Zheng B, Han J, Lin SC. Characterization of a novel mammalian RGS protein that binds to Ga proteins and inhibits pheromone signaling in yeast. J Biol Chem. 1997; 272: 8679-8685.
36. Gohla A, Klement K, Piekorz RP, Pexa K, vom Dahl S, Spicher K, Dreval V, Haussinger D, Birnbaumer L, Nurnberg B. An obligatory requirement for the heterotrimeric G protein Gi3 in the antiautophagic action of insulin in the liver. Proc Natl Acad Sci USA. 2007; 104: 3003-3008.
37. An JK, Blomenkamp K, Lindblad D, Teckman JH. Quantitative isolation of alpha1AT mutant Z protein polymers from human and mouse livers and the effect of heat. Hepatology. 2005; 41: 160-167.
38. Lindblad D, Blomenkamp K, Teckman J. Alpha-1-antitrypsin mutant Z protein content in individual hepatocytes correlates with cell death in a mouse model. Hepatology. 2007; 46: 1228-1235.
39. Hadzic N, Quaglia A, Mieli-Vergani G. Hepatocellular carcinoma in a 12-year-old child with PiZZ a1-antitrypsin deficiency. Hepatology. 2006; 46: 194.
40. Zhou H, Ortiz-Pallardo ME, Ko Y, Fischer H-P. Is heterozygous alpha-1-antitrypsin deficiency type PiZ a risk factor for primary liver cancer. Cancer. 2000; 88: 2688-2676.
41. Zhang L, Yu J, Pan H, Hu P, Hao Y, Cai W, Zhu H, Yu AD, Xie X, Ma D, et al. Small molecule regulators of autophagy identified by an image-based high-throughput screen. Proc Natl Acad Sci USA. 2007; 104: 19, 023-19, 028.